-
-
The 10-year disease-free and overall survival rate is presented from a trial of adjuvant therapy (chemo-, or immunotherapy) for Dukes B and C colon cancer conducted by the National Surgical Adjuvant Breast and Bowel cooperative group. The disease-free and overall survival advantage for the chemotherapy arm, apparent at 5 years, was no longer evident by 10 years.
-
Epirubicin and paclitaxel were administered either in combination or sequentially to 202 patients with metastatic breast cancer to demonstrate noninferiority of the sequential approach. Response rates and survival were comparable in the 2 groups, but toxicity was greater (neutropenia and neuropathy) in those that received the drugs sequentially rather than in combination.
-
Symptoms that are more severe or frequent than expected and of recent onset warrant further diagnostic investigation because they are more likely to be associated with both benign and malignant ovarian masses.
-
-
Annual, or less frequent, surveillance intervals are effective for aneurysms < 45 mm in diameter.
-
The benefit of ICD therapy, compared to amiodarone therapy in patients with life-threatening arrhythmia, continues to increase over time, and long-term data support the use of an ICD as first line therapy for secondary prevention of sudden cardiac death.
-
The National Cholesterol Education Program (NCEP), a product of a collaboration of the National Heart, Lung, and Blood Institutes, the American College of Cardiology, and the American Heart Association, has updated its clinical practice guideline on cholesterol management.
-
-
